Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease (Q33944053)

30 July 2017

1 reference

title

Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease (English)

1 reference

30 July 2017

1 reference

C Waters

1

1 reference

PubMed ID

10855610

30 July 2017

language of work or name

English

0 references

publication date

1 June 2000

1 reference

Journal of the American Geriatrics Society

30 July 2017

1 reference

30 July 2017

48

1 reference

30 July 2017

6

1 reference

30 July 2017

692-698

1 reference

COMT inhibition: a new treatment strategy for Parkinson's disease.

30 July 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB04732.X

Parkinson's disease. First of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB04732.X

Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB04732.X

Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB04732.X

Neostriatal mechanisms in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB04732.X

Managing the late complications of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB04732.X

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB04732.X

Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB04732.X

Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB04732.X

Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB04732.X

Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB04732.X

A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB04732.X

Hallucinosis in idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2000.TB04732.X

10.1111/J.1532-5415.2000.TB04732.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10855610